You are here

Article Text

Article menu
Download PDFPDF
Rare disease
Case report
Surgical-site mucormycosis infection in a solid-organ transplant recipient and a concise review of the literature
  1. Husham Haque1,
  2. Scott Nettboy1 and
  3. Sunil Kumar2
  1. 1 Internal Medicine, Broward Health Medical Center, Fort Lauderdale, Florida, USA
  2. 2 Pulmonary Critical Care, Broward Health Medical Center, Fort Lauderdale, Florida, USA
  1. Correspondence to Dr Husham Haque; hushamhaque{at}gmail.com

Abstract

Surgical-site mucormycosis infections in solid-organ transplant recipients are rare conditions, with only 15 previously reported cases. We describe a case of a 49-year-old man who received a liver transplant due to alcoholic cirrhosis. On postoperative day 14, necrosis was noticed at the surgical site. After mucormycosis was diagnosed, monotherapy with amphotericin was started along with surgical debridements. Due to continued clinical deterioration, triple antifungal therapy was started with amphotericin, micafungin and posaconazole. Treatment with a granulocyte-macrophage colony-stimulating factor was also started. Despite therapy, the patient expired on postoperative day 31. We review the risk factors for mucormycosis infection in solid-organ transplant recipients as well as evidence for current treatment options. We also review the 15 previously reported cases of surgical-site mucormycosis infections in solid-organ transplant recipients, including time to infection, infecting organisms, mortality and treatments.

  • drugs: infectious diseases
  • nosocomial infections
  • transplantation
  • liver disease

https://doi.org/10.1136/bcr-2019-229687

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors HH, SN and SK all conceptualised the design of the manuscript. HH, SN and SK all drafted the manuscript and revised the work for important intellectual content. HH, SN and SK all approve the version of the paper that has been submitted and are in agreement to be accountable for all aspects of the work.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Parental/guardian consent obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.